Nurix's $175M of­fer­ing; In­vivyd CEO is out

Plus, news about Agenus, Ger­resheimer and Oculis:

Nurix Ther­a­peu­tics’ $175M of­fer­ing: The pro­tein de­grad­er biotech up­sized its stock sale, which it will use pri­mar­i­ly to fund stud­ies of its three ear­ly-stage clin­i­cal drug can­di­dates, in­clud­ing two pro­tein de­graders for B-cell ma­lig­nan­cies. Nurix’s shares $NRIX jumped by around 11% in the past month af­ter the com­pa­ny an­nounced re­search deal ex­ten­sions with both Gilead and Sanofi, though the stock fell about 6% Fri­day morn­ing. — Lei Lei Wu

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.